Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study

Abstract

Patients with relapsed/refractory multiple myeloma (RRMM) resistant to multiple drug classes remain a high unmet need population. This longitudinal retrospective cohort study assessed real-world treatment patterns and outcomes in adults with RRMM. Patients who had three or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (double-exposed) were further categorized as refractory to a PI and an immunomodulatory agent (double-class refractory, n = 381) or additionally to an anti-CD38 monoclonal antibody (triple-class refractory, n = 173). Treatment options are limited for patients with double-class or triple-class refractory disease. Retreatment is a part of standard of care. Bortezomib and lenalidomide had the highest retreatment rates among double-class and triple-class refractory patients. Survival outcomes remain poor among RRMM patients with median overall survival (OS) of 22.3 and 11.6 months for double-class refractory and triple-class refractory patients, respectively. This study highlights the need for novel efficacious therapies in this heavily pretreated RRMM population.

Keywords:

• Treatment patterns
• myeloma
• pharmacotherapeutics

Acknowledgements

Writing assistance was provided by Elisabeth Walsby, PhD, of Fishawack Indica Ltd, part of Fishawack Health, and funded by GSK.

Disclosure statement

PFW, SF, BG, NB, and PP are employees of and have stocks and shares in GSK. MD, RHB, MLZ, CWY, AK, AN, and MSD are employees of Analysis Group, which received research funding from GSK.

Data availability statement

GSK makes available anonymized individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to www.clinicalstudydatarequest.com. To access data for other types of GSK sponsored research, for study documents without patient/participant-level data, and for clinical studies not listed, please submit an enquiry via the website.

Additional information

Funding

This study was funded by GSK (217353).